Læknablaðið - 15.10.2011, Side 15

RANNSÓKN
lýst hefur verið í erlendum rannsóknum, nema hvað hjartaöng er
heldur algengari. Skýringin gæti verið sú að hlutfall eldri sjúklinga
með kransæðasjúkdóm er hátt, en rúmur helmingur sjúklinga
gekkst undir kransæðahjáveituaðgerð samhliða lokuskiptum.
Rannsóknin er afturskyggn og óslembuð sem telst veikleiki,
sérstaklega þegar kemur að því að bera saman árangur
mismunandi lokutegunda. Þessi rannsókn getur því ekki svarað
því hvaða lífræna loka reyndist best, hvorki til skemmri né lengri
tíma. Ótvíræður styrkleiki þessarar rannsóknar er hins vegar að
í henni eru allir sjúklingar sem gengust undir ósæðarlokuskipti
hjá heilli þjóð á fimm ára tímabili. Aðeins þrír skurðlæknar
framkvæmdu aðgerðimar og nákvæmar upplýsingar lágu fyrir
um afdrif allra sjúklinga nema sjö.
í stuttu máli sagt eru snemmkomnir fylgikvillar algengir eftir
ósæðarlokuskipti vegna ósæðarlokuþrengsla, sérstaklega gáttatif
og enduraðgerð vegna blæðinga. Skurðdauði reyndist helmingi
tíðari eftir kransæðahjáveituaðgerðir sem einnig er þekkt í öðrum
rannsóknum.
Þakkir
Þakkir fær Gunnhildur Jóhannsdóttir, skrifstofustjóri á skurðdeild
Landspítala, en einnig Thor Aspelund tölfræðingur og Elín
Maríusdóttir læknir fyrir hjálp við tölfræðilega úrvinnslu. Rann-
sóknin var styrkt af Vísindasjóði Landspítala og Minningarsjóði
Bent Scheving Thorsteinssonar.
Heimildir
1. Freeman RV, Otto CM. Spectrum of calcific aortic valve
disease: pathogenesis, discasc progression, and treatment
strategies. Circulation 2005; 111: 3316-26.
2. Supino PG, Borer JS, Preibisz J, Bomstein A. The
epidemiology of valvular heart disease: a growing public
health problem. Heart Fail Clin 2006; 2: 379-93.
3. Iung B, Vahanian A. Epidemiology of valvular heart
disease in the adult. Nat Rev Cardiol 2011; 8:162-72.
4. Dworakowski R, MacCarthy P, Monaghan M, et al.
Transcatheter aortic valve implantation for severe aortic
stenosis-a new paradigm. Am Heart J 2010; 160:237-43.
5. Amórsson Þ, Torfason B, Ólafsson G, Alfreðsson H,
Jóhannsson KB, Guðbjartsson T. Hjartaskurðlækningar
á íslandi í 20 ár. Ágrip erinda af vísindaþingi Skurð-
læknafélags íslands og Svæfinga- og gjörgæslulæknafélags
íslands. E 24. Læknablaðið 2007; 93: 320.
6. Bonow RO, Carabello BA, Chatterjee K, et al. 2008
focused update incorporated into the ACC/AHA 2006
guidelines for the management of patients with valvular
heart disease: a report of the American College of
Cardiology/American Heart Association Task Force on
Practice Guidelines (Writing Committee to revise the 1998
guidelines for the management of patients with valvular
heart disease). Endorsed by the Society of Cardiovascular
Anesthesiologists, Society for Cardiovascular Angio-
graphy and Interventions, and Society of Thoracic Surge-
ons. J Am Coll Cardiol 2008; 52: el-142.
7. Horstkotte D, Schulte H, Bircks W, Strauer B. Unexpected
findings conceming thromboembolic complications and
anticoagulation after complete 10 year follow up of
patients with St. Jude Medical prostheses. J Heart Valve
Dis 1993; 2:291-301.
8. Pibarot P, Dumesnil JG. Prosthetic heart valves: selection
of the optimal prosthesis and long-term management.
Circulation 2009; 119:1034-48.
9. Maganti K, Rigolin VH, Sarano ME, Bonow RO. Valvular
heart disease: diagnosis and management. Mayo Clin Proc
2010; 85:483-500.
10. Doty JR, Flores JH, Millar RC, Doty DB. Aortic valve
replacement with medtronic freestyle bioprosthesis:
operative technique and results. J Card Surg 1998; 13: 208-
17.
11. Filardo G, Hamilton C, Hamman B, Hebeler RJ, Adams
J, Graybum P. New-onset postoperative atrial fibrillation
and long-term survival after aortic valve replacement
surgery. Ann Thorac Surg 2010; 90:474-9.
12. Mitchell L, Exner D, Wyse D, et al. Prophylactic Oral
Amiodarone for the Prevention of Arrhythmias that Begin
Early After Revascularization, Valve Replacement, or
Repair: PAPABEAR: a randomized controlled trial. 2005;
294:3093-100.
13. Helgadottir S, Sigurjónsson H, Ingvadottir IL, et al.
Gáttatif eftir opnar hjartaaðgerðir á íslandi. í: 12.
vísindaþing Skurðlæknafélags íslands og Svæfinga-
og gjörgæslulæknafélags íslands, 2010. E 27. www.
laeknabladid.is/fylgirit/fylgirit/2010/fylgirit62/-
september 2011
14. Aranki S, Shaw D, Adams D, et al. Predictors of atrial
fibrillation after coronary artery surgery. Current trends
and impact on hospital resources. Circulation 1996; 94:
390-7.
15. Camero-Alcazar M, Reguillo-Lacruz F, Alswies A,
Villagran-Medinilla E, Maroto-Castellanos LC, Rodriguez-
Hemandez J. Short- and mid-term results for aortic valve
replacement in octogenarians. Interact Cardiovasc Thorac
Surg 2010; 10:549-54.
16. Steingrímsson S, Gottfreðsson M, Kristinsson KG,
Guðbjartsson T. Deep stemal wound infections following
open heart surgery in Iceland: a population-based study.
Scan Cardiovasc J 2008; 42: 208-13.
17. Smárason NV, Sigurjónsson H, Hreinsson K, Amórsson T,
Guðbjartsson T. Enduraðgerðir vegna blæðinga eftir opnar
hjartaskurðaðgerðir. Læknablaðið 2009; 95: 567-73.
18. Gardner S, Gmnwald G, Rumsfeld J, et al. Comparison
of short-term mortality risk factors for valve replacement
versus coronary artery bypass graft surgery. Ann Thorac
Surg 2004; 77: 549-56.
19. Weerasinghe A, Yusuf M, Athanasiou T, Wood A, Magee P,
Uppal R. Role of transvalvular gradient in outcome from
valve replacement for aortic stenosis. Ann Thorac Surg
2004; 77:1266-71.
20. Ársrapport Swedeheart 2008: Riks-hia, Sephia, Scaar &
Hjártkimrgiregistret; 2008.
21. Emery RW, Krogh CC, Arom KV, et al. The St. Jude Medical
cardiac valve prosthesis: a 25-year experience with single
valve replacement. Ann Thorac Surg 2005; 79: 776-82;
discussion 82-3.
22. Khan SS, Trento A, DeRobertis M, et al. Twenty-year
comparison of tissue and mechanical valve replacement. J
Thorac Cardiovasc Surg 2001; 122:257-69.
23. Butchart EG, Li HH, Payne N, Buchan K, Grunkemeier GL.
Twenty years' experience with the Medtronic Hall valve. J
Thorac Cardiovasc Surg 2001; 121:1090-100.
24. Bach DS, Kon ND, Dumesnil JG, Sintek CF, Doty DB.
Ten-year outcome after aortic valve replacement with the
freestyle stentless bioprosthesis. Ann Thorac Surg 2005; 80:
480-6; discussion 6-7.
25. Eichinger WB, Hettich IM, Ruzicka DJ, et al. Twenty-year
experience with the St. Jude medical Biocor bioprosthesis
in the aortic position. Ann Thorac Surg 2008; 86:1204-10.
ENGLISH SUMMARY
Aortic valve replacement for aortic stenosis in lceland 2002-2006: Indications and short term complications
Ingvarsdóttir IL, Viktorsson SA, Hreinsson K, Sigurðsson Ml, Helgadóttir S, Arnórsson Þ, Danielsen R, Guðbjartsson T
Objective: Information on surgical outcome of aortic valve replacement (AVR) has not been available in lceland. We therefore studied the indications,
short-term complications and operative mortality in lcelandic patients that underwent AVR with aortic stenosis.
Material and methods: This was a retrospective study including all patients that underwent AVR for aortic stenosis at Landspitali between 2002 and
2006, a total of 156 patients (average age 71.7 years, 64.7% males). Short term complications and operative mortality (s30 days) were registered and risk
factors analysed with multivariate analysis.
Results: The most common symptoms before AVR were dyspnea (86.9%) and angina pectoris (52.6%). Preop. max aortic valve pressure gradient was
on average 74 mmHg, the left ventricular ejection fraction 57.2% and EuroSCORE (st) 6.9%. The average operating time was 282 min and concomitant
CABG was performed in 55% of the patients and mitral valve surgery in nine. A bioprothesis was implanted in 127 of the patients (81.4%), of which 102
were stentless valves, and a mechanical valve in 29 (18.6%) cases. The mean prosthesis size was 25.6 mm (range 21-29). Atrial fibrillation (78.0%) and
acute renal injury (36.0%) were the most common complications and 20 patients (13.0%) developed multiple-organ failure. Twenty-six patients (17.0%)
needed reoperation due to bleeding. Median hospital stay was 13 days and operative mortality was 6.4%.
Conclusions: The rate of short term complications following AVR was relatively high, including reoperations for bleeding and atrial fibrillation. Operative
mortality is twice that of CABG, which is in line with other studies.
Key words; Aortic valve replacement, aortic stenosis, outcome, eariy complications, operative mortality.
Correspondence; Tómas Guöbjartsson, tomasgud@landspitali.is
LÆKNAblaðið 2011/97 527